Skip to content

US · AQST · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Aquestive Therapeutics, Inc. (AQST) intrinsic value and stock valuation

$3.46as of 2026-11-21 · Mkt cap 471.13M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Aquestive Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values AQST with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from AQST’s statements →

Aquestive Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Warren, NJ 07059 aquestive.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$44.6M-0.6% 5y CAGRd
20162025
Net income
-$-83.78M
20162025
Free cash flow
-$-52.99M
20162025
Total equity
-$-33.66M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$44.6M$57.6M$50.6M$47.7M$50.8M
Operating income-$-69.65M-$-30.77M-$-15.1M-$-42.07M-$-34.68M
Net income-$-83.78M-$-44.14M-$-7.87M-$-54.41M-$-70.54M
EPSd-$-686.89K-$-508.94K-$-128.47K-$-1.12M-$-1.85M
Operating cash flow-$-52.43M-$-35.76M-$-6.38M-$-9.79M-$-32.98M
Capital expenditure-$-560K-$-160K-$-990K-$-2.52M-$-910K
Free cash flow-$-52.99M-$-35.92M-$-7.38M-$-12.31M-$-33.89M
Total assets$160.4M$101.4M$57.4M$57.1M$62M
Total debt$131.4M$38M$33.3M$57.5M$56.4M
Net debt$10.3M-$-33.54M$9.45M$30.2M$28.4M
Total equity-$-33.66M-$-60.16M-$-106.49M-$-118.55M-$-82.13M
Cash and short-term investments$121.2M$71.6M$23.9M$27.3M$28M
Income statement
20252024202320222021
Revenue$44.6M$57.6M$50.6M$47.7M$50.8M
Cost of revenue$17.2M$17.9M$20.8M$19.4M$15M
Gross profit$27.4M$39.7M$29.8M$28.3M$35.8M
Research and development expenses$17.2M$20.3M$13.1M$17.5M$17.1M
Selling, general and administrative expenses$79.9M$50.2M$31.8M$52.9M$53.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$97M$70.5M$44.9M$70.4M$70.5M
Cost and expenses$114.2M$88.3M$65.7M$89.8M$85.5M
Interest income$0.00$3.44M$16.3M$100K$420K
Interest expense$17.1M$16.8M$7.46M$12.4M$22.5M
Depreciation and amortization$560K$720K$1.34M$2.39M$2.96M
Ebitda-$-66.12M-$-26.62M$1.18M-$-39.58M-$-45.11M
Operating income-$-69.65M-$-30.77M-$-15.1M-$-42.07M-$-34.68M
Total other income/expenses, net-$-14.13M-$-13.38M$7.48M-$-12.34M-$-35.86M
Income before tax-$-83.78M-$-44.15M-$-7.62M-$-54.41M-$-70.54M
Income tax expense$0.00-$-10K$240K$0.00$0.00
Net income-$-83.78M-$-44.14M-$-7.87M-$-54.41M-$-70.54M
Weighted average shares outstanding$122M$86.7M$61.3M$48.7M$38.1M
Weighted average diluted shares outstanding$122M$86.7M$61.3M$48.7M$38.1M
Balance sheet
20252024202320222021
Cash and short-term investments$121.2M$71.6M$23.9M$27.3M$28M
Net receivables$17.8M$7.34M$8.47M$4.7M$12.1M
Inventory$6.17M$6.04M$6.77M$5.78M$4.04M
Total current assets$149.3M$88.2M$41M$39.9M$47.3M
Property, plant and equipment, net$8.51M$8.98M$9.74M$9.3M$7.78M
Goodwill and intangible assets$0.00$0.00$1.28M$1.44M$50K
Long-term investments$2M$3M$4M$0.00$6M
Total non-current assets$11.2M$13.2M$16.5M$17.2M$14.7M
Total assets$160.4M$101.4M$57.4M$57.1M$62M
Accounts payable$29.9M$10.3M$8.93M$9.95M$8.31M
Short-term debt$11.6M$540K$410K$19M$2.92M
Deferred revenue$1.09M$1.05M$1.55M$1.51M$770K
Total current liabilities$47.6M$18.9M$18.3M$39.5M$22M
Long-term debt$119.8M$37.5M$32.9M$38.5M$53.5M
Deferred revenue, non-current$19.4M$20M$32.3M$31.4M$7.12M
Total non-current liabilities$146.5M$142.7M$145.6M$136.1M$122.2M
Capital lease obligations$4.34M$5.48M$5.79M$5.34M$2.85M
Total liabilities$194.1M$161.6M$163.9M$175.6M$144.1M
Common stock$120K$90K$70K$60K$40K
Retained earnings-$-447M-$-363.21M-$-319.08M-$-311.21M-$-256.8M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-33.66M-$-60.16M-$-106.49M-$-118.55M-$-82.13M
Total investments$2M$3M$4M$0.00$6M
Total debt$131.4M$38M$33.3M$57.5M$56.4M
Net debt$10.3M-$-33.54M$9.45M$30.2M$28.4M
Cash flow statement
20252024202320222021
Net income-$-83.78M-$-44.14M-$-7.87M-$-54.41M-$-70.54M
Depreciation and amortization$550K$720K$1.34M$2.39M$2.96M
Stock-based compensation$7.62M$7.1M$2.69M$4.38M$6.82M
Change in working capital$12.2M-$-9.96M-$-5.34M$32M-$-1.73M
Accounts receivable-$-10.37M$1.09M-$-3.07M$7.35M-$-5.35M
Inventory-$-130K$720K-$-990K-$-1.74M-$-1.58M
Accounts payable$19.5M$2.78M-$-1.02M$1.63M$1.23M
Net cash provided by operating activities-$-52.43M-$-35.76M-$-6.38M-$-9.79M-$-32.98M
Investments in property, plant and equipment-$-560K-$-160K-$-990K-$-2.52M-$-910K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-560K-$-160K-$-990K-$-2.52M-$-910K
Common stock issued$103.5M$83.8M$8.91M$13.6M$29.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$102.6M$83.6M$3.97M$11.6M$30.1M
Net change in cash$49.6M$47.7M-$-3.4M-$-750K-$-3.78M
Cash at end of period$121.2M$71.6M$23.9M$27.3M$28M
Operating cash flow-$-52.43M-$-35.76M-$-6.38M-$-9.79M-$-32.98M
Capital expenditure-$-560K-$-160K-$-990K-$-2.52M-$-910K
Free cash flow-$-52.99M-$-35.92M-$-7.38M-$-12.31M-$-33.89M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Aquestive Therapeutics, Inc.

        Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.

        CEO
        Daniel Barber
        Employees
        147
        Beta
        1.45

        Explore

        Frequently asked questions

        What is the intrinsic value of Aquestive Therapeutics, Inc. (AQST)?

        Aquestive Therapeutics, Inc. (AQST) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AQST undervalued?

        AQST trades at a price of $3.46 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.